Scinai Immunotherapeutics (SCNI) reports Q1 2025 financial results with revenue growth and decreased net loss. Learn more about the biopharmaceutical company's performance and innovative pipeline.
This news matters as it highlights Scinai Immunotherapeutics' financial performance, showing revenue growth and reduced losses. Investors and stakeholders in the biopharmaceutical industry may find the company's expanding CDMO business and innovative pipeline of biological products of interest.